Silexion Therapeutics Execs to Seek Partners at BIO 2026
Event summary
- Silexion Therapeutics executives to attend BIO 2026 in San Diego June 22-25.
- CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar will host one-on-one meetings.
- Company advancing SIL204, a second-generation siRNA therapy, for KRAS-driven cancers.
- Phase 2a trial of first-generation product showed positive trends vs. chemotherapy.
- Silexion targeting locally advanced pancreatic cancer as lead indication.
The big picture
Silexion's attendance at BIO 2026 comes as RNAi therapies gain traction in oncology, particularly for KRAS mutations which represent a significant unmet need. The company's focus on pancreatic cancer positions it in one of the most challenging but high-need oncology segments. Success in partnering could accelerate its path to market, but competition in the RNAi space remains intense.
What we're watching
- Clinical Progress
- Whether SIL204 can demonstrate superior efficacy in upcoming trials compared to first-generation product.
- Partnering Strategy
- How aggressive Silexion will be in seeking collaborations at BIO 2026 to accelerate development.
- Regulatory Pathway
- The pace at which Silexion can secure approvals for clinical trials in Israel and the EU.
Related topics